Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
A feature article focusing on the recent updates to the American Society of Hematology guidelines for older adults with newly…
On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved an all-oral regimen of decitabine–cedazuridine (DEC-C; ASTX727) plus…
On May 13, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sonrotoclax for adults with relapsed/refractory…
We’re pleased to share a feature article focusing on the potential of hepcidin modulating agents in polycythemia vera.
VJHemOnc is excited to share this feature exploring the optimization of GPRC5D therapies in multiple myeloma.
VJHemOnc is thrilled to share our top picks from the 2026 EBMT-EHA CAR-T Meeting, featuring expert perspectives on the…
VJHemOnc is thrilled to bring you a feature article on the rise of disease modifying therapies in non-malignant hematology at…
On December 23, 2025, the U.S. Food and Drug Administration (FDA) granted approval to mitapivat for the treatment of adult…
VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.
VJHemOnc uses cookies, including analytics and marketing, to understand how the site is used and improve it. Optional cookies are on unless you turn them off.
Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.
You can change your choice at any time on our Cookie Policy page, linked at the bottom of every page.